June 22, 2020 / 6:14 AM / 23 days ago

BRIEF-Merck KGaA: EMA Validates Application For Cancer Drug Bavencio

June 22 (Reuters) - Merck KGaA:

* MERCK KGAA - EUROPEAN MEDICINES AGENCY VALIDATES APPLICATION FOR BAVENCIO® (AVELUMAB) FOR FIRST-LINE MAINTENANCE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

* A SUPPLEMENTAL NEW DRUG APPLICATION HAS ALSO BEEN ACCEPTED BY JAPAN’S MINISTRY OF HEALTH, LABOUR AND WELFARE FOR BAVENCIO AS A FIRST-LINE MAINTENANCE THERAPY FOR LOCALLY ADVANCED OR METASTATIC UC Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below